论文部分内容阅读
Cytosine-phosphate-guanosine (CpG) oligodeoxynucleotide 107 (CpG ODN107) is a novel radiosensitizer for the treatment of gliomas containing unmethylated CG dinucleotides.Despite its potential applications, information regarding its pharmacokinetics is lacking.To meet this need, we investigated the plasma pharmacokinetics, distribution, and elimination of CpG ODN107 in BALB/c mice via LC-MS/MS following intravenous injection at doses of 2.5, 5, and 10 mg/kg.While the plasma pharmacokinetics were not dose-dependent, elimination half-lives differed slightly with the dose and were, respectively, 0.65, 0.49, and 0.50 h, with CpG ODN107 found to be rapidly and widely distributed in organ tissues after intravenous injection, with the exception of the brain.